Patents by Inventor Michael Hope

Michael Hope has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240165263
    Abstract: The disclosure is generally related to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can target multiple classes of immune cells. Methods of making and using the nanoparticles are also provided herein. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen, and a second antigen that is a major histocompatibility complex type II (MHC-II) antigen.
    Type: Application
    Filed: March 30, 2022
    Publication date: May 23, 2024
    Inventors: Chad A. Mirkin, Michelle Hope Teplensky, Michael Evangelopoulos, Shuya Wang
  • Patent number: 11970789
    Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: April 30, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Gregory Charles Gordon, Robert Wayne Glenn, Mark Robert Sivik, Mark Ryan Richards, Stephen Wayne Heinzman, Michael David James, Geoffrey William Reynolds, Paul Dennis Trokhan, Paul Thomas Weisman, Alyssandrea Hope Hamad-Ebrahimpour, Frank William Denome, Stephen Joseph Hodson
  • Patent number: 11944693
    Abstract: A method for delivering one or more oral care active agents to a mammal's mouth using a nonwoven web of filaments and/or fibers containing one or more oral care active agents that are releasable from the filaments and/or fibers is provided.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: April 2, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Robert Wayne Glenn, Jr., Gregory Charles Gordon, Mark Robert Sivik, Mark Ryan Richards, Stephen Wayne Heinzman, Michael David James, Geoffrey William Reynolds, Paul Dennis Trokhan, Alyssandrea Hope Hamad-Ebrahimpour, Frank William Denome, Stephen Joseph Hodson
  • Publication number: 20220314078
    Abstract: In one aspect of the disclosure, a method includes rendering, by a processor, a virtual environment associating, by the processor, exercise machine control signals with the virtual environment, and displaying, by the processor, the virtual environment on a video wall. The method may include receiving, by the processor, a video of a trainer on an exercise machine in front of the video wall displaying the virtual environment, wherein the exercise machine has one or more parameters which are controlled according to the exercise machine control signals associated with the virtual environment, associating, by the processor, the control signals with the video of the trainer in the virtual environment, and publishing the video with the associated control signals for use on a remote exercise machine.
    Type: Application
    Filed: April 4, 2022
    Publication date: October 6, 2022
    Inventors: Eric Watterson, Nick Watterson, Joseph A. Torres, JR., Michael Hope
  • Publication number: 20150083433
    Abstract: A method for performing downhole gas lift operations includes coupling a gas lift valve to a tubing, wherein the gas lift valve includes an actuator, a flow control device disposed in the actuator, and a closure member that is initially in an open position; injecting a gas downhole and exterior to the tubing; urging the gas to enter the tubing via the gas lift valve; and creating a sufficient pressure differential across the gas lift valve to move the actuator, thereby causing the closure member to close the gas lift valve.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 26, 2015
    Inventors: Stephen David LONG, Zlatko SALIHBEGOVIC, J. Michael HOPE
  • Patent number: 7422902
    Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: September 9, 2008
    Assignee: The University of British Columbia
    Inventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
  • Publication number: 20070172950
    Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.
    Type: Application
    Filed: March 23, 2007
    Publication date: July 26, 2007
    Applicants: The University of British Columbia, INEX Pharmaceuticals Corporation
    Inventors: Jeffrey Wheeler, Marcel Bally, Yuan-Peng Zhang, Dorothy Reimer, Michael Hope, Pieter Cullis, Peter Scherrer
  • Publication number: 20060008909
    Abstract: The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.
    Type: Application
    Filed: May 16, 2005
    Publication date: January 12, 2006
    Applicant: Inex Pharmaceuticals Corporation
    Inventors: Pieter Cullis, Thomas Madden, Michael Hope, Steven Ansell, Barbara Mui, Sean Semple, Norbert Maurer
  • Publication number: 20050255153
    Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.
    Type: Application
    Filed: September 9, 2003
    Publication date: November 17, 2005
    Inventors: Sean Semple, Sandra Klimuk, Troy Harasym, Michael Hope, Steven Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
  • Publication number: 20050249794
    Abstract: Lipid-nucleic acid particles can provide therapeutic benefits, even when the nucleic acid is not complementary to coding sequences in target cells. It has been found that lipid-nucleic acid particles, including those containing non-sequence specific oligodeoxynucleotides, can be used to stimulate cytokine secretion, thus enhancing the overall immune response of a treated mammal. Further, immune response to specific target antigens can be induced by administration of a antigenic molecule in association with lipid particles containing non-sequence specific oligodeoxynucleotides. The nucleic acid which is included in the lipid-nucleic acid particle can be a phosphodiester (i.e.
    Type: Application
    Filed: February 26, 2004
    Publication date: November 10, 2005
    Inventors: Sean Semple, Troy Harasym, Sandra Klimuk, Ljiljiana Kojic, Jonathan Bramson, Barbara Mui, Michael Hope
  • Publication number: 20050079212
    Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 14, 2005
    Applicant: Inex Pharmaceuticals Corp.
    Inventors: Jeffery Wheeler, Michael Hope, Pieter Cullis, Marcel Bally
  • Patent number: 6858224
    Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: February 22, 2005
    Assignee: Inex Pharmaceuticals Corporation
    Inventors: Jeffrey Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope
  • Publication number: 20050008689
    Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.
    Type: Application
    Filed: August 24, 2004
    Publication date: January 13, 2005
    Inventors: Sean Semple, Sandra Klimuk, Troy Harasym, Michael Hope, Steven Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
  • Patent number: 6815432
    Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: November 9, 2004
    Assignee: Inex Pharmaceuticals Corp.
    Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
  • Publication number: 20030181410
    Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.
    Type: Application
    Filed: February 24, 2003
    Publication date: September 25, 2003
    Applicant: Inex Pharmaceuticals Corp.
    Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
  • Patent number: 6586410
    Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: July 1, 2003
    Assignee: Inex Pharmaceuticals Corporation
    Inventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
  • Patent number: 6534484
    Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: March 18, 2003
    Assignee: Inex Pharmaceuticals Corp.
    Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
  • Publication number: 20020192651
    Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.
    Type: Application
    Filed: June 5, 2001
    Publication date: December 19, 2002
    Inventors: Jeffrey Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope
  • Patent number: 6385226
    Abstract: A laser diode array assembly includes a laser diode array and a memory device integrally packaged with the array. The memory device includes operational information concerning the array. The memory device is accessible by a host external operating system which determines the manner in which the array is to be powered based on the operational information. The memory device may have the capability to be written to such that tie external operating system can record in the memory device significant events such as extreme operational conditions, operational faults, and the on-time or shot-count of the array. The assembly may include sensors to which the operating system is coupled. The assembly may further include a processing means to monitor the sensors and provide real-time updates to the external operating system such that laser diode array is continuously powered in an optimal manner.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: May 7, 2002
    Assignee: TRW Inc.
    Inventors: Theodore S. McMinn, Dana A. Marshall, Michael A. Hope, Geoffrey O. Heberle
  • Publication number: 20020006146
    Abstract: A laser diode array assembly includes a laser diode array and a memory device integrally packaged with the array. The memory device includes operational information concerning the array. The memory device is accessible by a host external operating system which determines the manner in which the array is to be powered based on the operational information. The memory device may have the capability to be written to such that the external operating system can record in the memory device significant events such as extreme operational conditions, operational faults, and the on-time or shotcount of the array. The assembly may include sensors to which the operating system is coupled. The assembly may further include a processing means to monitor the sensors and provide real-time updates to the external operating system such that laser diode array is continuously powered in an optimal manner.
    Type: Application
    Filed: August 6, 2001
    Publication date: January 17, 2002
    Inventors: Theodore S. McMinn, Dana A. Marshall, Michael A. Hope, Geoffrey O. Heberle